IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v34y2016i8d10.1007_s40273-016-0412-1.html
   My bibliography  Save this article

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

Author

Listed:
  • Jonathan Graham

    (RTI Health Solutions)

  • Doreen McBride

    (RTI Health Solutions)

  • Donald Stull

    (RTI Health Solutions)

  • Anna Halliday

    (Novartis Pharmaceuticals UK Limited)

  • Stamatia Theodora Alexopoulos

    (Novartis Pharmaceuticals UK Limited)

  • Maria-Magdalena Balp

    (Novartis Pharma AG)

  • Matthew Griffiths

    (Costello Medical Consulting Ltd)

  • Ion Agirrezabal

    (Costello Medical Consulting Ltd)

  • Torsten Zuberbier

    (Charité-University Hospital Berlin)

  • Alan Brennan

    (University of Sheffield)

Abstract

Background Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society. Objective The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective. Methods A Markov model was developed, consisting of health states based on Urticaria Activity Score over 7 days (UAS7) and additional states for relapse, spontaneous remission and death. Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case. The model considered early discontinuation of non-responders (response: UAS7 ≤6) and retreatment upon relapse (relapse: UAS7 ≥16) for responders. Clinical and cost inputs were derived from omalizumab trials and published sources, and cost utility was expressed as incremental cost-effectiveness ratios (ICERs). Scenario analyses included no early discontinuation of non-responders and an altered definition of response (UAS7

Suggested Citation

  • Jonathan Graham & Doreen McBride & Donald Stull & Anna Halliday & Stamatia Theodora Alexopoulos & Maria-Magdalena Balp & Matthew Griffiths & Ion Agirrezabal & Torsten Zuberbier & Alan Brennan, 2016. "Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria," PharmacoEconomics, Springer, vol. 34(8), pages 815-827, August.
    • Handle: RePEc:spr:pharme:v:34:y:2016:i:8:d:10.1007_s40273-016-0412-1
    DOI: 10.1007/s40273-016-0412-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-016-0412-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-016-0412-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:34:y:2016:i:8:d:10.1007_s40273-016-0412-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.